Collegium Pharmaceutical (COLL) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $31.5 million.
- Collegium Pharmaceutical's Income towards Parent Company rose 23751.47% to $31.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.4 million, marking a year-over-year decrease of 3403.28%. This contributed to the annual value of $42.4 million for FY2024, which is 788.23% down from last year.
- Per Collegium Pharmaceutical's latest filing, its Income towards Parent Company stood at $31.5 million for Q3 2025, which was up 23751.47% from $12.0 million recorded in Q2 2025.
- Collegium Pharmaceutical's 5-year Income towards Parent Company high stood at $72.8 million for Q2 2021, and its period low was -$25.0 million during Q4 2021.
- In the last 5 years, Collegium Pharmaceutical's Income towards Parent Company had a median value of $12.0 million in 2025 and averaged $11.0 million.
- The largest annual percentage gain for Collegium Pharmaceutical's Income towards Parent Company in the last 5 years was 757745.1% (2021), contrasted with its biggest fall of 45978.73% (2021).
- Quarter analysis of 5 years shows Collegium Pharmaceutical's Income towards Parent Company stood at -$25.0 million in 2021, then surged by 71.24% to -$7.2 million in 2022, then soared by 543.67% to $31.9 million in 2023, then plummeted by 60.75% to $12.5 million in 2024, then skyrocketed by 151.33% to $31.5 million in 2025.
- Its Income towards Parent Company was $31.5 million in Q3 2025, compared to $12.0 million in Q2 2025 and $2.4 million in Q1 2025.